158 related articles for article (PubMed ID: 38076664)
1. Treatment-Resistant Juvenile Depression-A Quicksand?
Naguy A; Pridmore S; Alhazeem H; Alamiri B
Psychopharmacol Bull; 2023 Dec; 53(4):54-56. PubMed ID: 38076664
[TBL] [Abstract][Full Text] [Related]
2. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
Hidalgo-Mazzei D; Berk M; Cipriani A; Cleare AJ; Florio AD; Dietch D; Geddes JR; Goodwin GM; Grunze H; Hayes JF; Jones I; Kasper S; Macritchie K; McAllister-Williams RH; Morriss R; Nayrouz S; Pappa S; Soares JC; Smith DJ; Suppes T; Talbot P; Vieta E; Watson S; Yatham LN; Young AH; Stokes PRA
Br J Psychiatry; 2019 Jan; 214(1):27-35. PubMed ID: 30520709
[TBL] [Abstract][Full Text] [Related]
3. Special Populations: Treatment-Resistant Depression in Children and Adolescents.
Ayvaci ER; Croarkin PE
Psychiatr Clin North Am; 2023 Jun; 46(2):359-370. PubMed ID: 37149350
[TBL] [Abstract][Full Text] [Related]
4. Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.
Medeiros da Frota Ribeiro C; Riva-Posse P
Curr Psychiatry Rep; 2017 Nov; 19(12):107. PubMed ID: 29138992
[TBL] [Abstract][Full Text] [Related]
5. Esketamine More Effective Than Quetiapine for Hard-to-Treat Depression.
Harris E
JAMA; 2023 Nov; 330(17):1611. PubMed ID: 37851473
[No Abstract] [Full Text] [Related]
6. Esketamine for treatment resistant depression: a trick of smoke and mirrors?
Gastaldon C; Papola D; Ostuzzi G; Barbui C
Epidemiol Psychiatr Sci; 2019 Dec; 29():e79. PubMed ID: 31841104
[TBL] [Abstract][Full Text] [Related]
7. The biology of depression in cancer and the relationship between depression and cancer progression.
Sotelo JL; Musselman D; Nemeroff C
Int Rev Psychiatry; 2014 Feb; 26(1):16-30. PubMed ID: 24716498
[TBL] [Abstract][Full Text] [Related]
8. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.
Singh I; Morgan C; Curran V; Nutt D; Schlag A; McShane R
Lancet Psychiatry; 2017 May; 4(5):419-426. PubMed ID: 28395988
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole Augmentation in Older Persons with Treatment-Resistant Depression.
Lewis G; Lewis G
N Engl J Med; 2023 Mar; 388(12):1137-1138. PubMed ID: 36867178
[No Abstract] [Full Text] [Related]
10. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q
PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863
[TBL] [Abstract][Full Text] [Related]
11. Assessing the risk factors for difficult-to-treat depression and treatment-resistant depression.
Gaynes B
J Clin Psychiatry; 2016 Feb; 77 Suppl 1():4-8. PubMed ID: 26829431
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5% dextrose on depressive symptoms in adults with treatment-resistant depression.
Mehdi SM; Atlas SE; Qadir S; Musselman D; Goldberg S; Woolger JM; Corredor R; Abbas MH; Arosemena L; Caccamo S; Campbell CS; Farooqi A; Gao J; Konefal J; Lages LC; Lantigua L; Lopez J; Padilla V; Rasul A; Ray AM; Simões HG; Tiozzo E; Lewis JE
Psychiatry Clin Neurosci; 2017 Mar; 71(3):204-211. PubMed ID: 27862658
[TBL] [Abstract][Full Text] [Related]
13. Treatment-resistant depression: are animal models of depression fit for purpose?
Willner P; Belzung C
Psychopharmacology (Berl); 2015 Oct; 232(19):3473-95. PubMed ID: 26289353
[TBL] [Abstract][Full Text] [Related]
14. Use of MAOIs in severe treatment-resistant depression: back to the old school.
Cookey J
J Psychiatry Neurosci; 2021 Jul; 46(4):E427-E428. PubMed ID: 34223742
[No Abstract] [Full Text] [Related]
15. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis.
Alnefeesi Y; Chen-Li D; Krane E; Jawad MY; Rodrigues NB; Ceban F; Di Vincenzo JD; Meshkat S; Ho RCM; Gill H; Teopiz KM; Cao B; Lee Y; McIntyre RS; Rosenblat JD
J Psychiatr Res; 2022 Jul; 151():693-709. PubMed ID: 35688035
[TBL] [Abstract][Full Text] [Related]
16. Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: an open trial.
Scantamburlo G; Hansenne M; Geenen V; Legros JJ; Ansseau M
Eur Psychiatry; 2015 Jan; 30(1):65-8. PubMed ID: 25282363
[TBL] [Abstract][Full Text] [Related]
17. Treatment-Resistant Depression: Approaches to Treatment.
Kverno KS; Mangano E
J Psychosoc Nurs Ment Health Serv; 2021 Sep; 59(9):7-11. PubMed ID: 34459676
[TBL] [Abstract][Full Text] [Related]
18. Ketamine and Treatment-Resistant Depression.
Lent JK; Arredondo A; Pugh MA; Austin PN
AANA J; 2019 Oct; 87(5):411-419. PubMed ID: 31612847
[TBL] [Abstract][Full Text] [Related]
19. Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity.
Lucchese AC; Sarin LM; Magalhães EJM; Del Sant LC; B Puertas C; Tuena MA; Nakahira C; Fava VA; Delfino R; Surjan J; Steiglich MS; Barbosa M; Abdo G; Cohrs FM; Liberatori A; Del Porto JA; Lacerda AL; B Andreoli S
J Psychopharmacol; 2021 Feb; 35(2):142-149. PubMed ID: 33427015
[TBL] [Abstract][Full Text] [Related]
20. Considerations for use of ketamine to treat depression in Australia and New Zealand.
Bayes A; Dong V; Loo C
Aust N Z J Psychiatry; 2019 Nov; 53(11):1117-1120. PubMed ID: 31364369
[No Abstract] [Full Text] [Related]
[Next] [New Search]
